261 related articles for article (PubMed ID: 36657815)
1. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
3. Venous thromboembolism risk in cancer patients receiving first-line immune checkpoint inhibitor versus chemotherapy.
Li A; May SB; La J; Martens KL; Amos CI; Flowers CR; Do NV; Brophy MT; Chitalia V; Ravid K; Gaziano JM; Fillmore NR
Am J Hematol; 2023 Aug; 98(8):1214-1222. PubMed ID: 37161855
[TBL] [Abstract][Full Text] [Related]
4. Thrombotic risk of platinum combination chemotherapy with and without immune checkpoint inhibitors for advanced non-small cell lung cancer: a nationwide inpatient database study.
Iwai C; Jo T; Konishi T; Fujita A; Michihata N; Matsui H; Fushimi K; Yasunaga H
Cancer Immunol Immunother; 2023 Nov; 72(11):3581-3591. PubMed ID: 37540262
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy.
Bjørnhart B; Kristiansen C; Asmussen J; Hansen KH; Wedervang K; Jørgensen TL; Herrstedt J; Schytte T
Thromb Res; 2023 Jan; 221():164-172. PubMed ID: 36396518
[TBL] [Abstract][Full Text] [Related]
6. Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study.
Beachler DC; Lamy FX; Kolitsopoulos F; Dinh J; Papazian A; Jamal-Allial A; Mahmoudpour SH; Michelon E; Verpillat P
Future Oncol; 2022 Aug; 18(26):2891-2901. PubMed ID: 35848218
[TBL] [Abstract][Full Text] [Related]
7. The incidence of venous thromboembolism among patients with primary lung cancer.
Chew HK; Davies AM; Wun T; Harvey D; Zhou H; White RH
J Thromb Haemost; 2008 Apr; 6(4):601-8. PubMed ID: 18208538
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study.
Wei Q; Deng T; Wu J; Zeng H; Qi C; Tan S; Zhang Y; Huang Q; Pu X; Xu W; Li W; Tian P; Li Y
BMC Cancer; 2024 Mar; 24(1):393. PubMed ID: 38549044
[TBL] [Abstract][Full Text] [Related]
9. The value of performance status in predicting venous thromboembolism in lung cancer patients treated with immune checkpoint inhibitors.
Zhang J; Yang L; Tian H; Xu R; Liu D
Eur J Oncol Nurs; 2024 Apr; 69():102527. PubMed ID: 38377652
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients.
He X; Wei SN; Qin WW; Geng N; Li B; Song S; Wang P
Expert Rev Hematol; 2023; 16(12):1135-1142. PubMed ID: 37883026
[TBL] [Abstract][Full Text] [Related]
11. Risk Factors of Venous Thromboembolic Disease in Cancer Patients Treated with Immune Checkpoint Inhibitor.
le Sève JD; Guédon AF; Bordenave S; Agard C; Connault J; Pistorius MA; Quéreux G; Espitia O
Thromb Haemost; 2023 Nov; 123(11):1049-1056. PubMed ID: 37257835
[TBL] [Abstract][Full Text] [Related]
12. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials.
Ma Z; Sun X; Zhang Y; Li H; Sun D; An Z; Zhang Y
Thromb Haemost; 2022 Oct; 122(10):1757-1766. PubMed ID: 35772727
[TBL] [Abstract][Full Text] [Related]
13. Immune Checkpoint Inhibitor-Related Pneumonitis in Lung Cancer: Real-World Incidence, Risk Factors, and Management Practices Across Six Health Care Centers in North Carolina.
Atchley WT; Alvarez C; Saxena-Beem S; Schwartz TA; Ishizawar RC; Patel KP; Rivera MP
Chest; 2021 Aug; 160(2):731-742. PubMed ID: 33621599
[TBL] [Abstract][Full Text] [Related]
14. Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study.
Icht O; Leader A; Batat E; Yosef L; Shochat T; Goldstein DA; Dudnik E; Spectre G; Raanani P; Hammerman A; Zer A
Oncologist; 2023 Jun; 28(6):e391-e396. PubMed ID: 37014824
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint inhibitors-associated thrombosis in patients with lung cancer and melanoma: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group.
Cánovas MS; Garay DF; Moran LO; Pérez JR; Rubio CMG; de Mena ML; Portero BO; Castro JB; Lage Y; Lavin DC; Blanco ABR; de Soignie AMMF; Perejón JZB; Colomo LJ; Boluda NB; Moreno JB; Verduguez TQ; Garrido CR; Huertas RM; Puig CFI; Martín AJM
Clin Transl Oncol; 2022 Oct; 24(10):2010-2020. PubMed ID: 35668339
[TBL] [Abstract][Full Text] [Related]
16. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
[TBL] [Abstract][Full Text] [Related]
17. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
Wong A; Riley M; Zhao S; Zimmer J; Viveiros M; Wang JG; Esguerra V; Li M; Lopez G; Kendra K; Carbone DP; He K; Alahmadi A; Kaufman J; Memmott RM; Shields PG; Brownstein J; Haglund K; Welliver M; Otterson GA; Presley CJ; Wei L; Owen DH; Ho K
J Natl Compr Canc Netw; 2023 Nov; 21(11):1164-1171.e5. PubMed ID: 37935100
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Uematsu S; Kitazono S; Tanaka H; Saito R; Kawashima Y; Ohyanagi F; Tozuka T; Ryosuke T; Sakatani T; Horiike A; Yoshizawa T; Saiki M; Tambo Y; Koyama J; Kanazu M; Kudo K; Tsuchiya-Kawano Y; Yanagitani N; Nishio M
Thorac Cancer; 2023 Jan; 14(2):168-176. PubMed ID: 36408699
[TBL] [Abstract][Full Text] [Related]
19. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors: a multi-institutional cohort study.
Tiu BC; Zubiri L; Iheke J; Pahalyants V; Theodosakis N; Ugwu-Dike P; Seo J; Tang K; Sise ME; Sullivan R; Naidoo J; Mooradian MJ; Semenov YR; Reynolds KL
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705313
[TBL] [Abstract][Full Text] [Related]
20. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
Gridelli C; Peters S; Mok T; Garassino M; Paz-Ares L; Attili I; de Marinis F
Lung Cancer; 2024 Jan; 187():107441. PubMed ID: 38141488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]